Wexford Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wexford Capital’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6,500	Closed	-$617K	–	269
2024 Q1	$617K	Buy	+6,500	New	+$603K	0.13%	113
2018 Q4	–	Sell	-35,266	Closed	-$3.38M	–	156
2018 Q3	$3.38M	Buy	+35,266	New	+$3.42M	0.22%	52
2017 Q4	–	Sell	-113,230	Closed	-$9.8M	–	169
2017 Q3	$9.8M	Buy	+113,230	New	+$9.08M	0.84%	26
2016 Q4	–	Sell	-82,180	Closed	-$5.45M	–	313
2016 Q3	$5.45M	Buy	+82,180	New	+$5.08M	0.89%	33

Other funds holding XBI

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Wexford Capital's XBI Position: Q2 2024 in Review

Wexford Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2024, closing a stake of 6,500 shares — an estimated $617K sold.

Wexford Capital first reported a position in XBI in Q3 2016 and held it in 4 quarters. The position peaked at $9.8M in Q3 2017. 762 funds tracked by Wall St. Rank hold XBI as of Q2 2024.

Wexford Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2024 after selling out during the quarter.
Wexford Capital sold 6,500 State Street SPDR S&P Biotech ETF shares in Q2 2024, an estimated $617K.
Wexford Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2016 and held it in 4 quarters.
Wexford Capital's State Street SPDR S&P Biotech ETF position peaked at $9.8M in Q3 2017.
762 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2024.

Based on Wexford Capital's 13F filing for Q2 2024, filed 14 Aug 2024.